Publications by authors named "Max Parker"

Claim this Profile
P
Predicting Early-Onset Colorectal Cancer in Individuals Below Screening Age Using Machine Learning and Real-World Data: Case Control Study.
Chengkun Sun, Erin Mobley, Michael Quillen, Max Parker, Meghan Daly, Alexander Parker

JMIR Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-Recording of Eye Movements in Amyotrophic Lateral Sclerosis Patients Using a Smartphone Eye-Tracking App.
Pouya Barahim Bastani, Ali S Saber Tehrani, Shervin Badihian, Hector Rieiro, David Rastall, Max Parker

Digit Biomark· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying Induced Nystagmus Using a Smartphone Eye Tracking Application (EyePhone).
Pouya B Bastani, Hector Rieiro, Shervin Badihian, Jorge Otero-Millan, Nathan Farrell, Max Parker

J Am Heart Assoc· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
J Jean Cui, Hong Shen, Michelle Tran-Dubé, Mitchell Nambu, Michele McTigue, Max Parker

J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
J Jean Cui, Michele McTigue, Mitchell Nambu, Michelle Tran-Dubé, Mason Pairish, Max Parker

J Med Chem· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor.
Helen Y Zou, Qiuhua Li, Joseph H Lee, Maria E Arango, Kristina Burgess, Max Parker

Mol Cancer Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis